This position paper supersedes the 2016 publication, “Malaria vaccine: WHO position paper-2016". It includes the updated WHO recommendations on the wider use of the RTS,S/AS01 vaccine for the reduction of malaria morbidity and mortality in children living in areas of moderate to high malaria transmission. It also incorporates findings from the evaluation of the WHO-coordinated Malaria Vaccine Implementation Programme (MVIP), recommended by SAGE and MPAG in 2015, and from additional studies since 2015. This paper does not include findings on vaccine efficacy in infants first vaccinated at 6–12 weeks of age. Because of the lower vaccine efficacy observed in this age category, WHO did not recommend pilot implementation or RTS,S/AS01 vaccine| introduction for these young infants. Recommendations on the use of RTS,S/AS01 vaccine were discussed by SAGE and MPAG during a joint session in October 2021.

Arabic | Chinese | Spanish

Related documents: